According to the product information for the hepatitis C virus (HCV) NS3/4A protease inhibitors, boceprevir
and telaprevir, plasma concentrations of the antidepressants desipramine
and trazodone may be increased when coadministered with these agents. The mechanism may involve inhibition of CYP450 3A4 metabolism. No pharmacokinetic data are currently available; however, adverse effects such as nausea, dizziness, hypotension, and syncope may be increased.